0000899243-21-007438.txt : 20210219
0000899243-21-007438.hdr.sgml : 20210219
20210219185054
ACCESSION NUMBER: 0000899243-21-007438
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210217
FILED AS OF DATE: 20210219
DATE AS OF CHANGE: 20210219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thompson Peter A.
CENTRAL INDEX KEY: 0001357522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40030
FILM NUMBER: 21657709
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
FORMER NAME:
FORMER CONFORMED NAME: Thompson Peter A
DATE OF NAME CHANGE: 20060327
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Decibel Therapeutics, Inc.
CENTRAL INDEX KEY: 0001656536
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464198709
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1325 BOYLSTON STREET
STREET 2: SUITE 500
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: 617-370-8701
MAIL ADDRESS:
STREET 1: 1325 BOYLSTON STREET
STREET 2: SUITE 500
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-17
0
0001656536
Decibel Therapeutics, Inc.
DBTX
0001357522
Thompson Peter A.
C/O DECIBEL THERAPEUTICS, INC.
1325 BOYLSTON STREET, SUITE 500
BOSTON
MA
02215
1
0
1
0
Common Stock
2021-02-17
4
C
0
2732106
A
2732106
I
See footnote
Common Stock
2021-02-17
4
C
0
327852
A
327852
I
See footnote
Common Stock
2021-02-17
4
C
0
218568
A
218568
I
See footnote
Common Stock
2021-02-17
4
P
0
1111100
18.00
A
3843206
I
See footnote
Common Stock
2021-02-17
4
P
0
555566
18.00
A
883418
I
See footnote
Series D Preferred Stock
2021-02-17
4
C
0
14480162
0.00
D
Common Stock
2732106
0
I
See footnote
Series D Preferred Stock
2021-02-17
4
C
0
1737619
0.00
D
Common Stock
327852
0
I
See footnote
Series D Preferred Stock
2021-02-17
4
C
0
1158412
0.00
D
Common Stock
218568
0
I
See footnote
On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationship, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor of OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM.
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.
/s/ Ronald Vigliotta, Attorney-in-Fact
2021-02-19